FDA-approved peptide medicines: the 2026 list

Many peptides are real FDA-approved medicines. This list gives 70 of them with brand, first approval year and labeled use, and explains what approval covers.

Basics8 min read

Key takeaway

Our library covers 70 FDA-approved peptide and small protein medicines, first approved between the 1950s and 2026. Approval covers a specific product and the uses on its label. It does not extend to compounded copies, supplements or research-grade material that share an ingredient name. Popular names such as BPC-157, TB-500 and retatrutide are not FDA-approved.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited0
Related productsResearch peptide catalog

Yes, many peptides are real, FDA-approved peptide medicines. They include semaglutide, tirzepatide, oxytocin, octreotide and leuprolide. Table 1 lists the 70 approved medicines that have a complete guide in our library, with each brand, first approval year and labeled use. Sources were checked on November 17, 2026.

Quick answer: FDA has approved dozens of peptide medicines, from insulin analogs and GLP-1 drugs to older hormones such as oxytocin and vasopressin. Nearly all are prescription medicines, and each has an official label. The newest in our list are enlicitide (Lipfendra) and rusfertide (Mimrylo), both approved in 2026. Being "a peptide" says nothing about whether a product is approved.

Which peptides are FDA-approved?

Table 1 is built from our library's complete guides for FDA-approved compounds. We checked each first approval year against Drugs@FDA or the label's initial U.S. approval date. Each name links to the guide, which links the official label. The table is not every peptide drug FDA has approved; liraglutide, for example, has no guide yet.

Table 1

FDA-approved peptide medicines in our library (checked November 17, 2026)

Medicine US brand First approved Labeled use, in short
AbaloparatideTymlos2017Osteoporosis in certain adults
AfamelanotideScenesse2019Light-triggered pain in EPP
Angiotensin IIGiapreza2017Low blood pressure in shock
BacitracinGeneric ointmentsBy 1971Minor wounds, some eye infections (injectable withdrawn)
BivalirudinAngiomax2000Anticoagulant during PCI
Bremelanotide (PT-141)Vyleesi2019Low sexual desire (HSDD) in premenopausal women
Calcitonin salmonMiacalcin1975Paget's disease, osteoporosis, high calcium
CetrorelixCetrotide2000Assisted reproduction
CorticotropinActhar Gel1950Infantile spasms, MS flares, other conditions
CosyntropinCortrosyn1970Adrenal function test
CyclosporineSandimmune, Neoral, Restasis1983Transplant rejection; dry eye
Dalbavancin, oritavancin, telavancinDalvance, Orbactiv, Vibativ2009Skin infections; pneumonia (Vibativ)
DaptomycinCubicin (discontinued); generics2003Skin and bloodstream infections
DasiglucagonZegalogue (discontinued)2021Severe low blood sugar
DegarelixFirmagon2008Advanced prostate cancer
DesirudinIprivask (discontinued)2003Clot prevention after hip replacement
DesmopressinDDAVP1978Diabetes insipidus, bedwetting, bleeding disorders
DifelikefalinKorsuva2021Itch in dialysis patients
EcallantideKalbitor2009Hereditary angioedema attacks
EchinocandinsEraxis, Rezzayo, generics2001Candida and some mold infections
Elamipretide (SS-31)Forzinity2025Muscle strength in Barth syndrome (accelerated)
EnfuvirtideFuzeon (discontinued)2003HIV-1 in treated patients
EnlicitideLipfendra2026High LDL cholesterol
EptifibatideIntegrilin (discontinued); generics1998Acute coronary syndrome, PCI
EtelcalcetideParsabiv2017Hyperparathyroidism on dialysis
Gallium Ga 68 dotatateNetspot2016PET scan of neuroendocrine tumors
GanirelixGeneric; Fyremadel1999Assisted reproduction
GlucagonBaqsimi, Gvoke, generics1960Severe low blood sugar
GoserelinZoladex1989Prostate and breast cancer, endometriosis
hCGPregnyl, Ovidrel, unbrandedBy 1973Fertility, hypogonadism (not weight loss)
HistrelinSupprelin LA; Vantas (discontinued)1991Early puberty
IcatibantFirazyr2011Hereditary angioedema attacks
Insulin analogsHumalog and others1996Blood sugar control in diabetes
LanreotideSomatuline Depot2007Acromegaly, neuroendocrine tumors
LeuprolideLupron Depot, Eligard1985Prostate cancer, endometriosis, early puberty
LinaclotideLinzess2012IBS-C, chronic constipation
Lutetium Lu 177 dotatateLutathera2018Neuroendocrine tumors
Lutetium Lu 177 vipivotide tetraxetanPluvicto2022PSMA-positive prostate cancer
MecaserminIncrelex2005Severe IGF-1 deficiency in children
MotixafortideAphexda2023Stem cell collection in myeloma
NafarelinSynarel1990Early puberty, endometriosis
NesiritideNatrecor (discontinued)2001Acute heart failure
OctreotideSandostatin, Mycapssa1988Acromegaly, carcinoid and VIPoma symptoms
OxytocinPitocin1980Labor and after delivery
PalopegteriparatideYorvipath2024Hypoparathyroidism in adults
Parathyroid hormoneNatpara (no longer supplied)2015Hypoparathyroidism
PasireotideSignifor2012Cushing's disease, acromegaly
PegcetacoplanEmpaveli, Syfovre2021PNH, kidney disease, geographic atrophy
PegvisomantSomavert2003Acromegaly
PlecanatideTrulance2017Chronic constipation, IBS-C
Polymyxin B and colistinGenericsBy 1964Serious gram-negative infections
RusfertideMimrylo2026Polycythemia vera
SecretinChiRhoStim2004Pancreas and gastrinoma tests
SemaglutideOzempic, Rybelsus, Wegovy2017Type 2 diabetes, weight, heart risk, MASH
SetmelanotideImcivree2020Certain rare genetic or hypothalamic obesity
SincalideKinevac1976Gallbladder and pancreas tests
SomapacitanSogroya2020Growth hormone deficiency
SomatropinGenotropin, Humatrope, others1987Growth failure; adult GH deficiency
TeduglutideGattex2012Short bowel syndrome
TerlipressinTerlivaz2022Hepatorenal syndrome
TeriparatideForteo (2002), Bonsity1987Osteoporosis in certain adults
TesamorelinEgrifta SV, Egrifta WR2010Belly fat in HIV lipodystrophy (not weight loss)
TirzepatideMounjaro, Zepbound2022Type 2 diabetes, weight, sleep apnea
TriptorelinTrelstar, Triptodur2000Prostate cancer, early puberty
TrofinetideDaybue2023Rett syndrome
VancomycinVancocin, generics1958Gram-positive infections, C. difficile
VasopressinVasostrict2014Low blood pressure in shock
VosoritideVoxzogo2021Growth in achondroplasia (accelerated)
ZiconotidePrialt2004Severe chronic pain
ZilucoplanZilbrysq2023Generalized myasthenia gravis

Notes on Table 1. "By" means the earliest dated record we found in Drugs@FDA; older records carry no date. Calcitonin salmon, somatropin, teriparatide and vancomycin use the initial U.S. approval year printed on current labels. "Accelerated" marks an indication approved under accelerated approval. Brands marked discontinued are listed that way in Drugs@FDA.

What counts as a peptide medicine?

A peptide is a short chain of amino acids. FDA draws a line in its rules. A protein is any amino acid chain of defined sequence "greater than 40 amino acids in size" (21 CFR 600.3). Chains of 40 or fewer fall below that line.

Some medicines in Table 1 sit above that line, such as insulin analogs, somatropin and hCG. We include them because our library covers them alongside the peptide hormones. Since March 23, 2020, approved applications for certain biological products, hCG among them, have been treated as biologics licenses (FDA, 2020). For the chemistry, see what a polypeptide is and types of peptides.

What does FDA approval cover, and what does it not?

Approval belongs to a specific product, made by a specific company, for the uses on its label. It does not pass to anything else that shares the ingredient's name.

  • Compounded drugs. FDA states that "compounded drugs are not FDA approved" and are not reviewed for safety, effectiveness or quality before sale (FDA, 2026).
  • Dietary supplements. "By statute, the FDA does not approve dietary supplements for safety and effectiveness."
  • Research-grade material. These are laboratory reagents for laboratory research use only, not for human or veterinary use, and they have no FDA label.

So a vial or pill sold online as "semaglutide" is not Ozempic or Wegovy. On who sets the dose, see semaglutide and tirzepatide dosage and where the dose of other peptide medicines comes from.

Which approved peptides are discontinued or no longer supplied?

Approval can outlast a product. Drugs@FDA lists these brands as discontinued: Zegalogue, Fuzeon, Iprivask, Natrecor, Vantas, Cubicin, Integrilin, Cancidas and Mycamine. Generic versions remain for several, including daptomycin, eptifibatide and caspofungin. For Cubicin, Drugs@FDA notes a Federal Register finding that it was not withdrawn for safety or effectiveness reasons (Drugs@FDA).

Two cases differ. Natpara's maker closed its U.S. special use program on December 31, 2025, with no shipments after that date (Takeda, 2025). For bacitracin, FDA asked in 2020 that approvals for the injectable form be withdrawn (Federal Register, 2022). Its first aid and eye products remain.

What does accelerated approval mean on this list?

Some approvals rest on an early measure of benefit and need later confirmation. The Voxzogo and Forzinity labels each state that the indication is approved under accelerated approval. Both add that continued approval may depend on confirmatory trials (Voxzogo label; Forzinity label). Wegovy's indication for MASH liver disease is also an accelerated approval (Wegovy label).

Which popular peptides are not FDA-approved?

Many peptides discussed online have no approval for any use. FDA says retatrutide has not been shown safe and effective for any condition. It "cannot be used in compounding under federal law" (FDA, 2026). BPC-157, TB-500, MOTS-c, KPV and others appear on FDA's list of compounding substances "previously in category 2," its significant-safety-risk group (FDA, 2026).

Our pages on retatrutide FDA approval, whether BPC-157 is legal and peptides and the FDA in 2026 explain where each stands. The legitimate routes to an unapproved drug are covered in how to find a peptide clinical trial.

How can you check a product's approval yourself?

  • Search Drugs@FDA by brand or ingredient. Each approved application shows its approval history and marketing status (Drugs@FDA).
  • Read the label on DailyMed, the National Library of Medicine's label database. It lists the approved uses and warnings.
  • Buy only through a licensed pharmacy. FDA's BeSafeRx pages list the signs of a safe online pharmacy, starting with one that "always requires a doctor's prescription."
  • Report problems to FDA through MedWatch, or call 1-888-INFO-FDA (1-888-463-6332) and press 2.

For the legal ways to get any of these medicines, see how to get peptides legally.

Frequently asked questions about FDA-approved peptides

Which peptides are FDA-approved?

Dozens, including semaglutide, tirzepatide, insulin analogs, oxytocin, octreotide, leuprolide, teriparatide and tesamorelin. Table 1 lists the 70 approved medicines covered in our library, with brand, first approval year and labeled use.

Are peptides FDA-approved?

Some are and many are not. Approval belongs to specific products for specific uses, so compounded copies, supplements and research-grade material are not FDA-approved even when they share a name.

Which peptides are FDA-approved for weight loss?

Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide) are approved for long-term weight management in eligible patients. Imcivree (setmelanotide) is approved for certain rare forms of obesity. All require a prescription.

Is BPC-157 FDA-approved?

No. BPC-157 has no FDA approval for any use, and FDA lists it among compounding substances previously in its significant-safety-risk category.

Is retatrutide FDA-approved?

No. As of November 17, 2026, retatrutide is an investigational drug, and FDA states it cannot be used in compounding under federal law.

Are compounded peptides FDA-approved?

No. FDA states that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are sold.

What to know now

  • Many approvals: 70 approved peptide and small protein medicines are covered in our library.
  • Product-specific: approval covers one product and its labeled uses, not copies.
  • Not approved: compounded drugs, supplements and research-grade material.
  • Popular but unapproved: retatrutide, BPC-157, TB-500 and MOTS-c.
  • Check it yourself: Drugs@FDA for approval, DailyMed for the label.

What we're watching

New peptide approvals. A possible FDA filing for retatrutide. Confirmatory results for the accelerated approvals on this list.

Also in the library

Sources: U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs (approval dates and marketing status for each product in Table 1, Drugs@FDA: FDA-approved drugs; U.S. Food and Drug Administration. openFDA: Drugs@FDA and drug labeling endpoints . https://open.fda.gov/apis/drug/drugsfda/, openFDA: Drugs@FDA and drug labeling endpoints; U.S. Food and Drug Administration. Drugs@FDA: NDA 021572 (Cubicin and Cubicin RF) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021572, Drugs@FDA: NDA 021572 (Cubicin and Cubicin RF); Electronic Code of Federal Regulations. 21 CFR 600.3: Definitions (paragraph (h)(6), 21 CFR 600.3: Definitions; U.S. Food and Drug Administration 2020, Notice to compounders: Changes that affect compounding on March 23, 2020; U.S. Food and Drug Administration 2026, Is it really "FDA approved"?; Takeda Pharmaceuticals U.S.A 2025; U.S. Food and Drug Administration 2022, Withdrawal of approval of bacitracin for injection; National Library of Medicine. DailyMed labels: Voxzogo and Forzinity (indications approved under accelerated approval). Voxzogo ; Forzinity, DailyMed labels: Voxzogo and Forzinity; National Library of Medicine. DailyMed: Wegovy (semaglutide) injection and tablets . https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b, DailyMed: Wegovy (semaglutide) injection and tablets; National Library of Medicine. DailyMed labels: Zepbound, DailyMed labels: Zepbound, Saxenda and Imcivree; U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2020, BeSafeRx: Considering an online pharmacy?; U.S. Food and Drug Administration 2025, Reporting serious problems to FDA (MedWatch). All 15 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs (approval dates and marketing status for each product in Table 1, checked November 17, 2026). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  2. U.S. Food and Drug Administration. openFDA: Drugs@FDA and drug labeling endpoints. https://open.fda.gov/apis/drug/drugsfda/
  3. U.S. Food and Drug Administration. Drugs@FDA: NDA 021572 (Cubicin and Cubicin RF). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021572
  4. Electronic Code of Federal Regulations. 21 CFR 600.3: Definitions (paragraph (h)(6), protein). https://www.ecfr.gov/current/title-21/section-600.3
  5. U.S. Food and Drug Administration. (2020). Notice to compounders: Changes that affect compounding on March 23, 2020. https://www.fda.gov/drugs/human-drug-compounding/notice-compounders-changes-affect-compounding-march-23-2020
  6. U.S. Food and Drug Administration. (2026). Is it really "FDA approved"? (content current as of May 4, 2026). https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved
  7. Takeda Pharmaceuticals U.S.A. (2025, December 2). Final notice: Natpara (parathyroid hormone) U.S. special use program closes December 31, 2025 (posted by FDA). https://www.fda.gov/media/189951/download
  8. U.S. Food and Drug Administration. (2022, July 11). Withdrawal of approval of bacitracin for injection. Federal Register, 87 FR 41135, document 2022-14680. https://www.govinfo.gov/content/pkg/FR-2022-07-11/html/2022-14680.htm
  9. National Library of Medicine. DailyMed labels: Voxzogo and Forzinity (indications approved under accelerated approval). Voxzogo; Forzinity
  10. National Library of Medicine. DailyMed: Wegovy (semaglutide) injection and tablets. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  11. National Library of Medicine. DailyMed labels: Zepbound, Saxenda and Imcivree. Zepbound; Saxenda; Imcivree
  12. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  13. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  14. U.S. Food and Drug Administration. (2020). BeSafeRx: Considering an online pharmacy? https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/considering-online-pharmacy
  15. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA (MedWatch). https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda